Oculis Holding AG: A Leading Biopharmaceutical Company Hosts R&D Day
Zug, Switzerland, April 15, 2025 – Oculis Holding AG, a distinguished biopharmaceutical company specializing in innovative solutions for ophthalmic and neuro-ophthalmic diseases with substantial unmet medical needs, is set to host an in-person and virtual R&D Day today, Tuesday, April 15, 2025, from 10:00 AM to 12:00 PM Eastern Time (ET) at the Intercontinental New York Barclay hotel.
Agenda and Registration
The event will offer attendees the opportunity to engage with Oculis’ executive leadership, scientific experts, and clinical development team. Participants can expect presentations on the Company’s pipeline, including updates on ongoing clinical trials, preclinical programs, and collaboration partnerships. To attend the event in person or participate virtually, interested parties are required to register here.
Oculis: Making a Difference in Ophthalmology
Oculis Holding AG, listed on Nasdaq under the ticker symbols OCS and XICE: OCS, has been at the forefront of developing novel therapies for various ophthalmic and neuro-ophthalmic conditions. The Company’s pipeline includes a diverse range of potential treatments, such as:
- OCU310: An investigational therapy for the treatment of neurotrophic keratitis, a severe corneal disease.
- OCU320: A potential treatment for retinal vein occlusion, a common cause of vision loss.
- OCU330: A novel approach for the treatment of diabetic macular edema, a leading cause of vision impairment and blindness in people with diabetes.
Impact on Individuals and the World
The progress made by Oculis Holding AG in the field of ophthalmology has the potential to significantly impact individuals’ lives and the world at large. For those suffering from ophthalmic and neuro-ophthalmic diseases, new and innovative treatments can mean the difference between maintaining or regaining their sight and experiencing vision loss or blindness. Moreover, these advancements can reduce the burden on healthcare systems and improve overall quality of life for affected individuals.
On a broader scale, the work being done by Oculis and other biopharmaceutical companies in the ophthalmology sector is crucial for addressing the growing global prevalence of eye diseases. According to the World Health Organization (WHO), approximately 285 million people worldwide are visually impaired, with 80% of these cases being avoidable. By continuing to invest in research and development, companies like Oculis can help reduce this number and improve overall eye health for millions of people around the world.
Conclusion
Oculis Holding AG’s R&D Day marks an exciting opportunity for investors, industry professionals, and the general public to learn more about the Company’s innovative pipeline and its potential to make a significant impact on individuals’ lives and the world. With a focus on addressing the unmet medical needs in ophthalmology and neuro-ophthalmology, Oculis is poised to contribute to the ongoing efforts to improve eye health and reduce vision loss and blindness.
For more information about Oculis Holding AG and its pipeline, please visit the Company’s website or attend the R&D Day event in person or virtually by registering here.
